Karpouzas GA, Ormseth SR, Hernandez E, et al. - Researchers undertook this single‐center observational cohort investigation to determine whether cardiovascular disease (CVD) risk in rheumatoid arthritis can be reduced by treatment with biologic disease‐modifying antirheumatic drugs (bDMARDs). They also inquired if potential benefits might be rendered by influencing coronary plaque formation or progression. This study involved 150 patients. The participants were asked to undergo computed tomography angiography for the assessment of coronary atherosclerosis (total, non‐calcified, mixed/calcified and low‐attenuation plaque). Within 6.9 ± 0.3 years, repeat evaluations were performed in 101 patients in order to assess plaque progression. Findings revealed that bDMARD use in rheumatoid arthritis was related to decreased CVD risk, protective calcification of non‐calcified lesions and lower chance of novel plaque formation among patients encountering early atherosclerosis.